Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Argus Health
US Army
McKesson
Boehringer Ingelheim
Medtronic
Novartis
Deloitte
Daiichi Sankyo

Generated: February 18, 2018

DrugPatentWatch Database Preview

Conivaptan hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for conivaptan hydrochloride and what is the scope of conivaptan hydrochloride freedom to operate?

Conivaptan hydrochloride
is the generic ingredient in two branded drugs marketed by Cumberland Pharms and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Conivaptan hydrochloride has twenty-nine patent family members in seventeen countries.

One supplier is listed for this compound.
Summary for conivaptan hydrochloride
Pharmacology for conivaptan hydrochloride

US Patents and Regulatory Information for conivaptan hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland Pharms VAPRISOL conivaptan hydrochloride INJECTABLE;IV (INFUSION) 021697-001 Dec 29, 2005 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Cumberland Pharms VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER conivaptan hydrochloride INJECTABLE;IV (INFUSION) 021697-002 Oct 8, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for conivaptan hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,856,564 Condensed benzazepine derivative and pharmaceutical composition thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for conivaptan hydrochloride

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Covington
Mallinckrodt
UBS
Colorcon
Cerilliant
Teva
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot